A global phase II trial of TransCon PTH in adult subjects with Hypoparathyroidism
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2019
At a glance
- Drugs TransCon PTH (Primary)
- Indications Hypoparathyroidism
- Focus Adverse reactions; Therapeutic Use
- Acronyms PaTH Forward
- Sponsors Ascendis Pharma
- 11 Feb 2019 According to an Ascendis Pharma media release, the company has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration for initiation of PaTH Forward trial.
- 07 Jan 2019 According to an Ascendis Pharma media release, top-line results this trial is expected in the fourth quarter of 2019.
- 28 Nov 2018 According to an Ascendis Pharma media release, the company plans to initiate this trial in the first quarter of 2019.